ProCE Banner Activity

Phase Ib TROPION-Lung04: Datopotamab Deruxtecan + Durvalumab ± Carboplatin in Advanced/Metastatic NSCLC

Conference Coverage

Preliminary analysis of the phase Ib TROPION-Lung04 trial showed promising antitumor responses and no unexpected safety signals in patients with advanced/metastatic NSCLC treated with Dato-DXd + durvalumab ± carboplatin.

Released: September 20, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences Inc., and Regeneron Pharmaceuticals, Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Regeneron Pharmaceuticals, Inc